- Home
- IVT vs RARE Comparison
IVT vs RARE Comparison
Compare IVT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- RARE
- Stock Information
- Founded
- IVT 2005
- RARE 2010
- Country
- IVT United States
- RARE United States
- Employees
- IVT N/A
- RARE N/A
- Industry
- IVT Real Estate Investment Trusts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- IVT Real Estate
- RARE Health Care
- Exchange
- IVT Nasdaq
- RARE Nasdaq
- Market Cap
- IVT 2.3B
- RARE 2.6B
- IPO Year
- IVT N/A
- RARE 2014
- Fundamental
- Price
- IVT $27.51
- RARE $30.04
- Analyst Decision
- IVT Buy
- RARE Strong Buy
- Analyst Count
- IVT 5
- RARE 14
- Target Price
- IVT $32.75
- RARE $86.64
- AVG Volume (30 Days)
- IVT 473.7K
- RARE 1.8M
- Earning Date
- IVT 10-28-2025
- RARE 11-04-2025
- Dividend Yield
- IVT 3.46%
- RARE N/A
- EPS Growth
- IVT 1533.99
- RARE N/A
- EPS
- IVT 1.47
- RARE N/A
- Revenue
- IVT $287,075,000.00
- RARE $610,159,000.00
- Revenue This Year
- IVT $9.70
- RARE $19.72
- Revenue Next Year
- IVT $8.25
- RARE $23.29
- P/E Ratio
- IVT $18.65
- RARE N/A
- Revenue Growth
- IVT 9.17
- RARE 26.77
- 52 Week Low
- IVT $25.21
- RARE $25.81
- 52 Week High
- IVT $31.65
- RARE $58.00
- Technical
- Relative Strength Index (RSI)
- IVT 27.11
- RARE 51.17
- Support Level
- IVT $29.27
- RARE $29.60
- Resistance Level
- IVT $30.20
- RARE $31.70
- Average True Range (ATR)
- IVT 0.42
- RARE 1.22
- MACD
- IVT -0.24
- RARE 0.15
- Stochastic Oscillator
- IVT 7.50
- RARE 60.51
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.